Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Karuna Therapeutics (NASDAQ:KRTX) fell as much as 7.6% and has now pared the loss to 1.6% on no apparent news. Bristol-Myers (NYSE:BMY) agreed to acquire neuroscience drug firm Karuna (KRTX ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off. The ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

topping out with Bristol Myers Squibb’s $14 billion buyout of Karuna Therapeutics. Still to come in the first quarter of 2024 were four more acquisitions worth at least $2.5 billion, topped off ...